Neurotoxicity of Cancer Chemotherapy

ABSTRACT

Neurologic dysfunction is a common side effect of many chemotherapy drugs. For several agents, neurotoxicity is common, severe, and can be dose-limiting. As the list of newer chemotherapy agents and systemic “targeted therapies” grows, so does the number and variety of potential neurotoxicities. This is a review of the clinical features of chemotherapy-induced syndromes involving the central and peripheral nervous systems.

KEYWORDS

Chemotherapy adverse effects - polyneuropathy

REFERENCES

• 1 Vassal G, Deroussent A, Hartmann O et al.. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study.  Cancer Res. 1990;  50(19) 6203-6207
• 2 Wyllie A R, Bayliff C D, Kovacs M J. Myoclonus due to chlorambucil in two adults with lymphoma.  Ann Pharmacother. 1997;  31(2) 171-174
• 3 Dropcho E J, Rosenfeld S S, Vitek J, Guthrie B L, Morawetz R B. Phase II study of intracarotid or selective intracerebral infusion of cisplatin for treatment of recurrent anaplastic gliomas.  J Neurooncol. 1998;  36(2) 191-198
• 4 Baker W J, Royer Jr G L, Weiss R B. Cytarabine and neurologic toxicity.  J Clin Oncol. 1991;  9(4) 679-693
• 5 Jaeckle K A, Batchelor T, O'Day S J et al.. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis.  J Neurooncol. 2002;  57(3) 231-239
• 6 Jabbour E, O'Brien S, Kantarjian H et al.. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia.  Blood. 2007;  109(8) 3214-3218
• 7 Leff R S, Thompson J M, Daly M B et al.. Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma.  Cancer. 1988;  62(1) 32-35
• 8 Pratt C B, Green A A, Horowitz M E et al.. Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna.  J Clin Oncol. 1986;  4(8) 1253-1261
• 9 Pratt C B, Goren M P, Meyer W H, Singh B, Dodge R K. Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors.  J Clin Oncol. 1990;  8(8) 1399-1401
• 10 Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prové A, Vermorken J B. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.  Br J Cancer. 2000;  82(2) 291-294
• 11 Rieger C, Fiegl M, Tischer J, Ostermann H, Schiel X. Incidence and severity of ifosfamide-induced encephalopathy.  Anticancer Drugs. 2004;  15(4) 347-350
• 12 Ajithkumar T, Parkinson C, Shamshad F, Murray P. Ifosfamide encephalopathy.  Clin Oncol (R Coll Radiol). 2007;  19 108-114
• 13 DiMaggio J R, Brown R, Baile W F, Schapira D. Hallucinations and ifosfamide-induced neurotoxicity.  Cancer. 1994;  73(5) 1509-1514
• 14 Simonian N A, Gilliam F G, Chiappa K H. Ifosfamide causes a diazepam-sensitive encephalopathy.  Neurology. 1993;  43(12) 2700-2702
• 15 Buesa J M, García-Teijido P, Losa R, Fra J. Treatment of ifosfamide encephalopathy with intravenous thiamin.  Clin Cancer Res. 2003;  9(12) 4636-4637
• 16 Pavol M A, Meyers C A, Rexer J L, Valentine A D, Mattis P J, Talpaz M. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia.  Neurology. 1995;  45(5) 947-950
• 17 Valentine A D, Meyers C A, Kling M A, Richelson E, Hauser P. Mood and cognitive side effects of interferon-alpha therapy.  Semin Oncol. 1998;  25(1, Suppl 1) 39-47
• 18 Hensley M L, Peterson B, Silver R T, Larson R A, Schiffer C A, Szatrowski T P. Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013.  J Clin Oncol. 2000;  18(6) 1301-1308
• 19 Adams F, Fernandez F, Mavligit G. Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities.  J Neurooncol. 1988;  6(4) 355-359
• 20 Meyers C A, Scheibel R S, Forman A D. Persistent neurotoxicity of systemically administered interferon-alpha.  Neurology. 1991;  41(5) 672-676
• 21 Musselman D L, Lawson D H, Gumnick J F et al.. Paroxetine for the prevention of depression induced by high-dose interferon alfa.  N Engl J Med. 2001;  344(13) 961-966
• 22 Denicoff K D, Rubinow D R, Papa M Z et al.. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells.  Ann Intern Med. 1987;  107(3) 293-300
• 23 Karp B I, Yang J C, Khorsand M, Wood R, Merigan T C. Multiple cerebral lesions complicating therapy with interleukin-2.  Neurology. 1996;  47(2) 417-424
• 24 Baz D V, Bofill J S, Nogueira J A. Irinotecan-induced dysarthria.  J Natl Cancer Inst. 2001;  93(18) 1419-1420
• 25 Nieto Y, Cagnoni P J, Bearman S I et al.. Acute encephalopathy: a new toxicity associated with high-dose paclitaxel.  Clin Cancer Res. 1999;  5(3) 501-506
• 26 Perry J R, Warner E. Transient encephalopathy after paclitaxel (Taxol) infusion.  Neurology. 1996;  46(6) 1596-1599
• 27 Ziske C G, Schöttker B, Gorschlüter M et al.. Acute transient encephalopathy after paclitaxel infusion: report of three cases.  Ann Oncol. 2002;  13(4) 629-631
• 28 Rook J, Rosser T, Fangusaro J, Finlay J. Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma.  Pediatr Blood Cancer. 2008;  50(3) 699-700
• 29 Byrd R L, Rohrbaugh T M, Raney Jr R B, Norris D G. Transient cortical blindness secondary to vincristine therapy in childhood malignancies.  Cancer. 1981;  47(1) 37-40
• 30 Hurwitz R L, Mahoney Jr D H, Armstrong D L, Browder T M. Reversible encephalopathy and seizures as a result of conventional vincristine administration.  Med Pediatr Oncol. 1988;  16(3) 216-219
• 31 Jansen C E, Miaskowski C, Dodd M, Dowling G, Kramer J. A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function.  Cancer. 2005;  104(10) 2222-2233
• 32 Kayl A E, Wefel J S, Meyers C A. Chemotherapy and cognition: effects, potential mechanisms, and management.  Am J Ther. 2006;  13(4) 362-369
• 33 Vardy J, Rourke S, Tannock I F. Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research.  J Clin Oncol. 2007;  25(17) 2455-2463
• 34 Wefel J S, Lenzi R, Theriault R, Buzdar A U, Cruickshank S, Meyers C A. “Chemobrain” in breast carcinoma? A prologue.  Cancer. 2004;  101(3) 466-475
• 35 Hermelink K, Untch M, Lux M P et al.. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study.  Cancer. 2007;  109(9) 1905-1913
• 36 Inagaki M, Yoshikawa E, Matsuoka Y et al.. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy.  Cancer. 2007;  109(1) 146-156
• 37 Silverman D H, Dy C J, Castellon S A et al.. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy.  Breast Cancer Res Treat. 2007;  103(3) 303-311
• 38 Ahles T A, Saykin A J. Candidate mechanisms for chemotherapy-induced cognitive changes.  Nat Rev Cancer. 2007;  7(3) 192-201
• 39 Rosenblum M K, Delattre J Y, Walker R W, Shapiro W R. Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathological study.  J Neurooncol. 1989;  7(3) 269-281
• 40 Hook C C, Kimmel D W, Kvols L K et al.. Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole.  Ann Neurol. 1992;  31(3) 262-267
• 41 Savarese D M, Gordon J, Smith T W et al.. Cerebral demyelination syndrome in a patient treated with 5-fluorouracil and levamisole. The use of thallium SPECT imaging to assist in noninvasive diagnosis—a case report.  Cancer. 1996;  77(2) 387-394
• 42 Franco D A, Greenberg H S. 5-FU multifocal inflammatory leukoencephalopathy and dihydropyrimidine dehydrogenase deficiency.  Neurology. 2001;  56(1) 110-112
• 43 Takimoto C H, Lu Z H, Zhang R et al.. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency.  Clin Cancer Res. 1996;  2(3) 477-481
• 44 Videnovic A, Semenov I, Chua-Adajar R et al.. Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.  Neurology. 2005;  65(11) 1792-1794 discussion 1685
• 45 Robain O, Dulac O, Dommergues J P et al.. Necrotising leukoencephalopathy complicating treatment of childhood leukaemia.  J Neurol Neurosurg Psychiatry. 1984;  47(1) 65-72
• 46 Correa D D, DeAngelis L M, Shi W, Thaler H, Glass A, Abrey L E. Cognitive functions in survivors of primary central nervous system lymphoma.  Neurology. 2004;  62(4) 548-555
• 47 Harder H, Holtel H, Bromberg J E et al.. Cognitive status and quality of life after treatment for primary CNS lymphoma.  Neurology. 2004;  62(4) 544-547
• 48 Herrlinger U, Küker W, Uhl M Neuro-Oncology Working Group of the German Society et al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report.  Ann Neurol. 2005;  57(6) 843-847
• 49 Kingma A, van Dommelen R I, Mooyaart E L et al.. Slight cognitive impairment and magnetic resonance imaging abnormalities but normal school levels in children treated for acute lymphoblastic leukemia with chemotherapy only.  J Pediatr. 2001;  139 413-420
• 50 Montour-Proulx I, Kuehn S M, Keene D L et al.. Cognitive changes in children treated for acute lymphoblastic leukemia with chemotherapy only according to the Pediatric Oncology Group 9605 protocol.  J Child Neurol. 2005;  20(2) 129-133
• 51 Reddick W E, Glass J O, Helton K J, Langston J W, Li C S, Pui C H. A quantitative MR imaging assessment of leukoencephalopathy in children treated for acute lymphoblastic leukemia without irradiation.  AJNR Am J Neuroradiol. 2005;  26(9) 2371-2377
• 52 Omuro A M, Ben-Porat L S, Panageas K S et al.. Delayed neurotoxicity in primary central nervous system lymphoma.  Arch Neurol. 2005;  62(10) 1595-1600
• 53 Oka M, Terae S, Kobayashi R et al.. MRI in methotrexate-related leukoencephalopathy: disseminated necrotising leukoencephalopathy in comparison with mild leukoencephalopathy.  Neuroradiology. 2003;  45(7) 493-497
• 54 Rubinstein L J, Herman M M, Long T F, Wilbur J R. Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma.  Cancer. 1975;  35(2) 291-305
• 55 Lai R, Abrey L E, Rosenblum M K, DeAngelis L M. Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study.  Neurology. 2004;  62(3) 451-456
• 56 Linnebank M, Moskau S, Jürgens A et al.. Association of genetic variants of methionine metabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma.  Neuro-oncol. 2009;  11(1) 2-8
• 57 Chun H G, Leyland-Jones B R, Caryk S M, Hoth D F. Central nervous system toxicity of fludarabine phosphate.  Cancer Treat Rep. 1986;  70(10) 1225-1228
• 58 Cheson B D, Vena D A, Foss F M, Sorensen J M. Neurotoxicity of purine analogs: a review.  J Clin Oncol. 1994;  12(10) 2216-2228
• 59 Cohen R B, Abdallah J M, Gray J R, Foss F. Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia.  Ann Intern Med. 1993;  118(2) 114-116
• 60 Feinberg W M, Swenson M R. Cerebrovascular complications of L-asparaginase therapy.  Neurology. 1988;  38(1) 127-133
• 61 Mitchell L G, Andrew M, Hanna K Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase Group (PARKAA) et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.  Cancer. 2003;  97(2) 508-516
• 62 Scappaticci F A, Skillings J R, Holden S N et al.. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.  J Natl Cancer Inst. 2007;  99(16) 1232-1239
• 63 Zangari M, Fink L M, Elice F, Zhan F, Adcock D M, Tricot G J. Thrombotic events in patients with cancer receiving antiangiogenesis agents.  J Clin Oncol. 2009;  27(29) 4865-4873
• 64 Norden A D, Young G S, Setayesh K et al.. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.  Neurology. 2008;  70(10) 779-787
• 65 Narayana A, Kelly P, Golfinos J et al.. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.  J Neurosurg. 2009;  110(1) 173-180
• 66 Friedman H S, Prados M D, Wen P Y et al.. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.  J Clin Oncol. 2009;  27(28) 4733-4740
• 67 Nghiemphu P L, Green R M, Pope W B, Lai A, Cloughesy T F. Safety of anticoagulation use and bevacizumab in patients with glioma.  Neuro-oncol. 2008;  10(3) 355-360
• 68 Carden C P, Larkin J M, Rosenthal M A. What is the risk of intracranial bleeding during anti-VEGF therapy?.  Neuro-oncol. 2008;  10(4) 624-630
• 69 El Amrani M, Heinzlef O, Debroucker T, Roullet E, Bousser M G, Amarenco P. Brain infarction following 5-fluorouracil and cisplatin therapy.  Neurology. 1998;  51(3) 899-901
• 70 Serrano-Castro P J, Guardado-Santervás P, Olivares-Romero J. Ischemic stroke following cisplatin and 5-fluorouracil therapy: a transcranial Doppler study.  Eur Neurol. 2000;  44(1) 63-64
• 71 Russmann S, Winkler A, Lövblad K O, Stanga Z, Bassetti C. Lethal ischemic stroke after cisplatin-based chemotherapy for testicular carcinoma and cannabis inhalation.  Eur Neurol. 2002;  48(3) 178-180
• 72 Dietrich J, Marienhagen J, Schalke B, Bogdahn U, Schlachetzki F. Vascular neurotoxicity following chemotherapy with cisplatin, ifosfamide, and etoposide.  Ann Pharmacother. 2004;  38(2) 242-246
• 73 Bernard J T, Ameriso S, Kempf R A, Rosen P, Mitchell M S, Fisher M. Transient focal neurologic deficits complicating interleukin-2 therapy.  Neurology. 1990;  40(1) 154-155
• 74 Walker R W, Allen J C, Rosen G, Caparros B. Transient cerebral dysfunction secondary to high-dose methotrexate.  J Clin Oncol. 1986;  4(12) 1845-1850
• 75 Rubnitz J E, Relling M V, Harrison P L et al.. Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia.  Leukemia. 1998;  12(8) 1176-1181
• 76 Eichler A F, Batchelor T T, Henson J W. Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate.  Neuro-oncol. 2007;  9(3) 373-377
• 77 Inaba H, Khan R B, Laningham F H, Crews K R, Pui C H, Daw N C. Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer.  Ann Oncol. 2008;  19(1) 178-184
• 78 Rollins N, Winick N, Bash R, Booth T. Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome.  AJNR Am J Neuroradiol. 2004;  25(10) 1688-1695
• 79 Fisher M J, Khademian Z P, Simon E M, Zimmerman R A, Bilaniuk L T. Diffusion-weighted MR imaging of early methotrexate-related neurotoxicity in children.  AJNR Am J Neuroradiol. 2005;  26(7) 1686-1689
• 80 Haykin M E, Gorman M, van Hoff J, Fulbright R K, Baehring J M. Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity.  J Neurooncol. 2006;  76 153-157
• 81 Balin J, Parmar H, Kujawski L. Conventional and diffusion-weighted MRI findings of methotrexate related sub-acute neurotoxicity.  J Neurol Sci. 2008;  269(1-2) 169-171
• 82 Drachtman R A, Cole P D, Golden C B et al.. Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity.  Pediatr Hematol Oncol. 2002;  19(5) 319-327
• 83 Jaksic W, Veljkovic D, Pozza C, Lewis I. Methotrexate-induced leukoencephalopathy reversed by aminophylline and high-dose folinic acid.  Acta Haematol. 2004;  111(4) 230-232
• 84 Ay H, Buonanno F S, Schaefer P W et al.. Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI.  Neurology. 1998;  51(5) 1369-1376
• 85 Tam C S, Galanos J, Seymour J F, Pitman A G, Stark R J, Prince H M. Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies.  Am J Hematol. 2004;  77(1) 72-76
• 86 Sánchez-Carpintero R, Narbona J, López de Mesa R, Arbizu J, Sierrasesúmaga L. Transient posterior encephalopathy induced by chemotherapy in children.  Pediatr Neurol. 2001;  24(2) 145-148
• 87 Suminoe A, Matsuzaki A, Kira R et al.. Reversible posterior leukoencephalopathy syndrome in children with cancers.  J Pediatr Hematol Oncol. 2003;  25(3) 236-239
• 88 Morris E B, Laningham F H, Sandlund J T, Khan R B. Posterior reversible encephalopathy syndrome in children with cancer.  Pediatr Blood Cancer. 2007;  48(2) 152-159
• 89 Shin R K, Stern J W, Janss A J, Hunter J V, Liu G T. Reversible posterior leukoencephalopathy during the treatment of acute lymphoblastic leukemia.  Neurology. 2001;  56(3) 388-391
• 90 Allen J A, Adlakha A, Bergethon P R. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.  Arch Neurol. 2006;  63(10) 1475-1478
• 91 Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab.  N Engl J Med. 2006;  354(9) 980-982 discussion 980-982
• 92 Henderson R D, Rajah T, Nicol A J, Read S J. Posterior leukoencephalopathy following intrathecal chemotherapy with MRA-documented vasospasm.  Neurology. 2003;  60(2) 326-328
• 93 Covarrubias D J, Luetmer P H, Campeau N G. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images.  AJNR Am J Neuroradiol. 2002;  23(6) 1038-1048
• 94 Smith G A, Damon L E, Rugo H S, Ries C A, Linker C A. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency.  J Clin Oncol. 1997;  15(2) 833-839
• 95 Winkelman M D, Hines J D. Cerebellar degeneration caused by high-dose cytosine arabinoside: a clinicopathological study.  Ann Neurol. 1983;  14(5) 520-527
• 96 Pirzada N A, Ali I I, Dafer R M. Fluorouracil-induced neurotoxicity.  Ann Pharmacother. 2000;  34(1) 35-38
• 97 Brashear A, Siemers E. Focal dystonia after chemotherapy: a case series.  J Neurooncol. 1997;  34(2) 163-167
• 98 Anderson N R, Tandon D S. Ifosfamide extrapyramidal neurotoxicity.  Cancer. 1991;  68(1) 72-75
• 99 Resar L M, Phillips P C, Kastan M B, Leventhal B G, Bowman P W, Civin C I. Acute neurotoxicity after intrathecal cytosine arabinoside in two adolescents with acute lymphoblastic leukemia of B-cell type.  Cancer. 1993;  71(1) 117-123
• 100 Raney B, Tefft M, Heyn R et al.. Ascending myelitis after intensive chemotherapy and radiation therapy in children with cranial parameningeal sarcoma.  Cancer. 1992;  69(6) 1498-1506
• 101 McLean D R, Clink H M, Ernst P et al.. Myelopathy after intrathecal chemotherapy. A case report with unique magnetic resonance imaging changes.  Cancer. 1994;  73(12) 3037-3040
• 102 Kleinschmidt-DeMasters B K, Yeh M. “Locked-in syndrome” after intrathecal cytosine arabinoside therapy for malignant immunoblastic lymphoma.  Cancer. 1992;  70(10) 2504-2507
• 103 Richardson P G, Briemberg H, Jagannath S et al.. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.  J Clin Oncol. 2006;  24(19) 3113-3120
• 104 Badros A, Goloubeva O, Dalal J S et al.. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.  Cancer. 2007;  110(5) 1042-1049
• 105 Argyriou A A, Iconomou G, Kalofonos H P. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.  Blood. 2008;  112(5) 1593-1599
• 106 San Miguel J F, Schlag R, Khuageva N K VISTA Trial Investigators et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.  N Engl J Med. 2008;  359(9) 906-917
• 107 Siegal T, Haim N. Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps.  Cancer. 1990;  66(6) 1117-1123
• 108 Cavaletti G, Marzorati L, Bogliun G et al.. Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity.  Cancer. 1992;  69(1) 203-207
• 109 Ta L E, Espeset L, Podratz J, Windebank A J. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding.  Neurotoxicology. 2006;  27(6) 992-1002
• 110 McWhinney S R, Goldberg R M, McLeod H L. Platinum neurotoxicity pharmacogenetics.  Mol Cancer Ther. 2009;  8(1) 10-16
• 111 Dzagnidze A, Katsarava Z, Makhalova J et al.. Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy.  J Neurosci. 2007;  27(35) 9451-9457
• 112 Boogerd W, ten Bokkel Huinink W W, Dalesio O, Hoppenbrouwers W J, van der Sande J J. Cisplatin induced neuropathy: central, peripheral and autonomic nerve involvement.  J Neurooncol. 1990;  9(3) 255-263
• 113 Strumberg D, Brügge S, Korn M W et al.. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer.  Ann Oncol. 2002;  13(2) 229-236
• 114 Heinzlef O, Lotz J P, Roullet E. Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy.  J Neurol Neurosurg Psychiatry. 1998;  64(5) 667-669
• 115 Openshaw H, Slatkin N E, Stein A S, Hinton D R, Forman S J. Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia.  Cancer. 1996;  78(9) 1899-1905
• 116 Lee J J, Low J A, Croarkin E et al.. Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone.  J Clin Oncol. 2006;  24(13) 2084-2091
• 117 Imrie K R, Couture F, Turner C C, Sutcliffe S B, Keating A. Peripheral neuropathy following high-dose etoposide and autologous bone marrow transplantation.  Bone Marrow Transplant. 1994;  13(1) 77-79
• 118 Stein M E, Drumea K, Yarnitsky D, Benny A, Tzuk-Shina T. A rare event of 5-fluorouracil-associated peripheral neuropathy: a report of two patients.  Am J Clin Oncol. 1998;  21(3) 248-249
• 119 Saif M W, Wilson R H, Harold N, Keith B, Dougherty D S, Grem J L. Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil.  Anticancer Drugs. 2001;  12(6) 525-531
• 120 Saif M W, Wood T E, McGee P J, Diasio R B. Peripheral neuropathy associated with capecitabine.  Anticancer Drugs. 2004;  15(8) 767-771
• 121 Frisk P, Stålberg E, Strömberg B, Jakobson A. Painful peripheral neuropathy after treatment with high-dose ifosfamide.  Med Pediatr Oncol. 2001;  37(4) 379-382
• 122 Patel S R, Forman A D, Benjamin R S. High-dose ifosfamide-induced exacerbation of peripheral neuropathy.  J Natl Cancer Inst. 1994;  86(4) 305-306
• 123 Koh S, Nelson Jr M D, Kovanlikaya A, Chen L S. Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment.  Pediatr Neurol. 1999;  21(2) 576-578
• 124 Bay A, Oner A F, Etlik O, Yilmaz C, Caksen H. Myelopathy due to intrathecal chemotherapy: report of six cases.  J Pediatr Hematol Oncol. 2005;  27(5) 270-272
• 125 Pascual A M, Coret F, Casanova B, Láinez M J. Anterior lumbosacral polyradiculopathy after intrathecal administration of methotrexate.  J Neurol Sci. 2008;  267(1-2) 158-161
• 126 Argyriou A A, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos H P. A review on oxaliplatin-induced peripheral nerve damage.  Cancer Treat Rev. 2008;  34(4) 368-377
• 127 Wilson R H, Lehky T, Thomas R R, Quinn M G, Floeter M K, Grem J L. Acute oxaliplatin-induced peripheral nerve hyperexcitability.  J Clin Oncol. 2002;  20(7) 1767-1774
• 128 Lehky T J, Leonard G D, Wilson R H, Grem J L, Floeter M K. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy.  Muscle Nerve. 2004;  29(3) 387-392
• 129 Webster R G, Brain K L, Wilson R H, Grem J L, Vincent A. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels.  Br J Pharmacol. 2005;  146(7) 1027-1039
• 130 Krishnan A V, Goldstein D, Friedlander M, Kiernan M C. Oxaliplatin and axonal Na + channel function in vivo.  Clin Cancer Res. 2006;  12(15) 4481-4484
• 131 Taieb S, Trillet-Lenoir V, Rambaud L, Descos L, Freyer G. Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients.  Cancer. 2002;  94(9) 2434-2440
• 132 Krishnan A V, Goldstein D, Friedlander M, Kiernan M C. Oxaliplatin-induced neurotoxicity and the development of neuropathy.  Muscle Nerve. 2005;  32(1) 51-60
• 133 Park S B, Lin C S, Krishnan A V, Goldstein D, Friedlander M L, Kiernan M C. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.  Brain. 2009;  132(Pt 10) 2712-2723
• 134 Land S R, Kopec J A, Cecchini R S et al.. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.  J Clin Oncol. 2007;  25(16) 2205-2211
• 135 Durand J P, Alexandre J, Guillevin L, Goldwasser F. Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy.  Anticancer Drugs. 2005;  16(5) 587-591
• 136 Argyriou A A, Chroni E, Polychronopoulos P et al.. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy.  Neurology. 2006;  67(12) 2253-2255
• 137 Gamelin L, Boisdron-Celle M, Delva R et al.. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer.  Clin Cancer Res. 2004;  10(12 Pt 1) 4055-4061
• 138 Gamelin L, Capitain O, Morel A et al.. Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway.  Clin Cancer Res. 2007;  13(21) 6359-6368
• 139 Chaudhry V, Eisenberger M A, Sinibaldi V J, Sheikh K, Griffin J W, Cornblath D R. A prospective study of suramin-induced peripheral neuropathy.  Brain. 1996;  119(Pt 6) 2039-2052
• 140 Soliven B, Dhand U K, Kobayashi K et al.. Evaluation of neuropathy in patients on suramin treatment.  Muscle Nerve. 1997;  20(1) 83-91
• 141 Cavaletti G, Bogliun G, Marzorati L et al.. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin.  Cancer. 1995;  75(5) 1141-1150
• 142 Forsyth P A, Balmaceda C, Peterson K, Seidman A D, Brasher P, DeAngelis L M. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing.  J Neurooncol. 1997;  35(1) 47-53
• 143 Hilkens P H, Verweij J, Stoter G, Vecht C J, van Putten W L, van den Bent M J. Peripheral neurotoxicity induced by docetaxel.  Neurology. 1996;  46(1) 104-108
• 144 New P Z, Jackson C E, Rinaldi D, Burris H, Barohn R J. Peripheral neuropathy secondary to docetaxel (Taxotere).  Neurology. 1996;  46(1) 108-111
• 145 Persohn E, Canta A, Schoepfer S et al.. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats.  Eur J Cancer. 2005;  41(10) 1460-1466
• 146 Lee J J, Swain S M. Peripheral neuropathy induced by microtubule-stabilizing agents.  J Clin Oncol. 2006;  24(10) 1633-1642
• 147 Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes.  Eur J Cancer. 2006;  42(1) 24-30
• 148 van den Bent M J, Hilkens P H, Sillevis Smitt P A, van Raaij-van den Aarssen V J, Bontenbal M, Verweij J. Lhermitte's sign following chemotherapy with docetaxel.  Neurology. 1998;  50(2) 563-564
• 149 Chaudhry V, Rowinsky E K, Sartorius S E, Donehower R C, Cornblath D R. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies.  Ann Neurol. 1994;  35(3) 304-311
• 150 Freilich R J, Balmaceda C, Seidman A D, Rubin M, DeAngelis L M. Motor neuropathy due to docetaxel and paclitaxel.  Neurology. 1996;  47(1) 115-118
• 151 Chaudhry V, Chaudhry M, Crawford T O, Simmons-O'Brien E, Griffin J W. Toxic neuropathy in patients with pre-existing neuropathy.  Neurology. 2003;  60(2) 337-340
• 152 Berger T, Malayeri R, Doppelbauer A et al.. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy.  Eur J Cancer. 1997;  33(9) 1393-1399
• 153 Cavaletti G, Beronio A, Reni L et al.. Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study.  Neurology. 2004;  62(12) 2291-2293
• 154 Molloy F M, Floeter M K, Syed N A et al.. Thalidomide neuropathy in patients treated for metastatic prostate cancer.  Muscle Nerve. 2001;  24(8) 1050-1057
• 155 Chaudhry V, Cornblath D R, Corse A, Freimer M, Simmons-O'Brien E, Vogelsang G. Thalidomide-induced neuropathy.  Neurology. 2002;  59(12) 1872-1875
• 156 Tosi P, Zamagni E, Cellini C et al.. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.  Eur J Haematol. 2005;  74(3) 212-216
• 157 Offidani M, Corvatta L, Marconi M et al.. Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy.  Eur J Haematol. 2004;  72(6) 403-409
• 158 Mileshkin L, Stark R, Day B, Seymour J F, Zeldis J B, Prince H M. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.  J Clin Oncol. 2006;  24(27) 4507-4514
• 159 Plasmati R, Pastorelli F, Cavo M et al.. Neuropathy in multiple myeloma treated with thalidomide: a prospective study.  Neurology. 2007;  69(6) 573-581
• 160 Casey E B, Jellife A M, Le Quesne P M, Millett Y L. Vincristine neuropathy. Clinical and electrophysiological observations.  Brain. 1973;  96(1) 69-86
• 161 Verstappen C C, Koeppen S, Heimans J J et al.. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening.  Neurology. 2005;  64(6) 1076-1077
• 162 Graf W D, Chance P F, Lensch M W, Eng L J, Lipe H P, Bird T D. Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A.  Cancer. 1996;  77(7) 1356-1362
• 163 Hildebrandt G, Holler E, Woenkhaus M et al.. Acute deterioration of Charcot-Marie-Tooth disease IA (CMT IA) following 2 mg of vincristine chemotherapy.  Ann Oncol. 2000;  11(6) 743-747
• 164 Kalfakis N, Panas M, Karadima G, Floroskufi P, Kokolakis N, Vassilopoulos D. Hereditary neuropathy with liability to pressure palsies emerging during vincristine treatment.  Neurology. 2002;  59(9) 1470-1471
• 165 Weintraub M, Adde M A, Venzon D J et al.. Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine.  J Clin Oncol. 1996;  14(3) 935-940
• 166 Pace A, Bove L, Nisticò C et al.. Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients.  J Neurol Neurosurg Psychiatry. 1996;  61(4) 409-411
• 167 Apfel S C. Managing the neurotoxicity of paclitaxel (Taxol) and docetaxel (Taxotere) with neurotrophic factors.  Cancer Invest. 2000;  18(6) 564-573
• 168 Cavaletti G, Zanna C. Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity.  Eur J Cancer. 2002;  38(14) 1832-1837
• 169 Leong S S, Tan E H, Fong K W et al.. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer.  J Clin Oncol. 2003;  21(9) 1767-1774
• 170 Lorusso D, Ferrandina G, Greggi S Multicenter Italian Trials in Ovarian Cancer invesitgators et al. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients.  Ann Oncol. 2003;  14(7) 1086-1093
• 171 Openshaw H, Beamon K, Synold T W et al.. Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine.  Clin Cancer Res. 2004;  10(2) 461-467
• 172 De Vos F Y, Bos A M, Schaapveld M et al.. A randomized phase II study of paclitaxel with carboplatin + /- amifostine as first line treatment in advanced ovarian carcinoma.  Gynecol Oncol. 2005;  97(1) 60-67
• 173 Hensley M L, Hagerty K L, Kewalramani T et al.. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.  J Clin Oncol. 2009;  27(1) 127-145
• 174 Cascinu S, Catalano V, Cordella L et al.. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial.  J Clin Oncol. 2002;  20(16) 3478-3483
• 175 Argyriou A A, Chroni E, Koutras A et al.. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial.  Neurology. 2005;  64(1) 26-31
• 176 Bianchi G, Vitali G, Caraceni A et al.. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine.  Eur J Cancer. 2005;  41(12) 1746-1750
• 177 Maestri A, De Pasquale Ceratti A, Cundari S, Zanna C, Cortesi E, Crinò L. A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy.  Tumori. 2005;  91(2) 135-138